RECRUITING

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Official Title

Multi-Modality Detection of RCC Recurrence Post Ablation

Quick Facts

Study Start:2022-11-03
Study Completion:2028-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05641935

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Previously received cryotherapy or microwave therapy of RCC
  2. * Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
  3. * Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
  4. * Be at least 18 years of age
  5. * Be medically stable
  6. * If a female of child-bearing age, must have a negative pregnancy test
  7. * Have signed Informed Consent to participate in the study
  1. * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
  2. * Patients with known sensitivities to the components of Lumason

Contacts and Locations

Study Contact

John Eisenbrey, PhD
CONTACT
215-503-5188
john.eisenbrey@jefferson.edu

Study Locations (Sites)

Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: john eisenbrey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-03
Study Completion Date2028-02

Study Record Updates

Study Start Date2022-11-03
Study Completion Date2028-02

Terms related to this study

Additional Relevant MeSH Terms

  • Recurrent Renal Cell Carcinoma
  • Renal Cell Carcinoma